MetLife, Inc. logo MET - MetLife, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 25
HOLD 8
SELL 0
STRONG
SELL
0
| PRICE TARGET: $98.22 DETAILS
HIGH: $105.00
LOW: $90.00
MEDIAN: $96.00
CONSENSUS: $98.22
UPSIDE: 0.75%
AlphaVal

AlphaVal

Deterministic, archetype-aware fair value

Banks, Insurers & Asset Managers 85% confidence

Primary model: P/Tangible Book × ROE Quality

Valuation Signal Overvalued Mild
Trading 6.2% above fair value
Current Price $97.49
Bear Case $64.29 34.1% downside ($64.29 - $97.49) / $97.49 = -34.1% ROTCE 8.9% → 1.08x TBV
Fair Value $91.84 5.8% downside ($91.84 - $97.49) / $97.49 = -5.8% ROTCE 11.9% → 1.72x TBV
Bull Case $119.39 22.5% upside ($119.39 - $97.49) / $97.49 = 22.5% ROTCE 13.7% → 2.11x TBV

Adjust Assumptions

11.9%
8.6%

Key Value Driver

ROTCE (11.9%) vs. cost of equity (8.6%)

Implied Market Multiple 2.21x

Plain-Language Summary

Our base-case estimate uses P/Tangible Book × ROE Quality. We then blend that result with the average analyst price target of $98.22 from 33 analysts, using a 30% weight on analyst consensus. That produces an estimated intrinsic value of $91.84 per share.

Warnings

Traditional cash flow models don't work well for banks — lending activity distorts how much cash the business actually generates.
Common valuation shortcuts don't apply here — for banks, interest payments are a core business cost, not overhead.
Dividend-based valuation: $46.60 (48% below our primary estimate). Large gaps suggest the dividend may not fully reflect the company's value.

Key Risks

  • Book value quality matters as much as level — check loan loss reserves
  • Interest rate sensitivity creates non-linear earnings surprises
  • Insurance reserving is actuarial, not financial — errors emerge slowly